Login / Signup

The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer.

Barbara L MeloskyParneet CheemaRosalyn A JuergensNatasha B LeighlGeoffrey LiuPaul Wheatley-PriceAdrian SacherStephanie SnowMing-Sound TsaoDeanna McLeodQuincy Siu-Chung Chu
Published in: Therapeutic advances in medical oncology (2021)
Adjuvant osimertinib used alone or following platinum-based chemotherapy is now recommended in patients with stage II-IIIA EGFR-mutated NSCLC.
Keyphrases
  • small cell lung cancer
  • epidermal growth factor receptor
  • early stage
  • advanced non small cell lung cancer
  • brain metastases
  • tyrosine kinase
  • lymph node
  • locally advanced
  • prognostic factors